4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Volume 37 Issue 2
Mar.  2023
Turn off MathJax
Article Contents
Abstract
Introduction
SIRT3
Mitochondrial biogenesis
Dysregulation of mitochondrial biogenesis in aging-related diseases
Interaction between SIRT3 and mitochondrial biogenesis in aging-related diseases
Neurodegenerative diseases
Cardiovascular diseases
Type 2 diabetes mellitus
Conclusions and perspectives
Fundings
Acknowledgments
References
Related Articles
Hongyan Li, Zhiyou Cai. SIRT3 regulates mitochondrial biogenesis in aging-related diseases[J]. The Journal of Biomedical Research, 2023, 37(2): 77-88. DOI: 10.7555/JBR.36.20220078
Citation: Hongyan Li, Zhiyou Cai. SIRT3 regulates mitochondrial biogenesis in aging-related diseases[J]. The Journal of Biomedical Research, 2023, 37(2): 77-88. DOI: 10.7555/JBR.36.20220078
shu

SIRT3 regulates mitochondrial biogenesis in aging-related diseases

  • 1.

    Department of Neurology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

  • 2.

    Department of Neurology, Chongqing General Hospital, Chongqing 400013, China

More Information
  • Corresponding author:

    Zhiyou Cai, Southwest Medical University, Luzhou, Sichuan 646000, China; Department of Neurology, Chongqing General Hospital, No. 312 Zhongshan First Road, Yuzhong District, Chongqing 400013, China. Tel/Fax: +86-23-63515796, E-mail: caizhiyou@ucas.ac.cn

  • Received Date: April 09, 2022
  • Revised Date: May 25, 2022
  • Accepted Date: May 31, 2022
  • Available Online: June 27, 2022
    Graphical Abstract
    • Abstract
  • Sirtuin 3 (SIRT3), the main family member of mitochondrial deacetylase, targets the majority of substrates controlling mitochondrial biogenesis via lysine deacetylation and modulates important cellular functions such as energy metabolism, reactive oxygen species production and clearance, oxidative stress, and aging. Deletion of SIRT3 has a deleterious effect on mitochondrial biogenesis, thus leading to the defect in mitochondrial function and insufficient ATP production. Imbalance of mitochondrial dynamics leads to excessive mitochondrial biogenesis, dampening mitochondrial function. Mitochondrial dysfunction plays an important role in several diseases related to aging, such as cardiovascular disease, cancer and neurodegenerative diseases. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) launches mitochondrial biogenesis through activating nuclear respiratory factors. These factors act on genes, transcribing and translating mitochondrial DNA to generate new mitochondria. PGC1α builds a bridge between SIRT3 and mitochondrial biogenesis. This review described the involvement of SIRT3 and mitochondrial dynamics, particularly mitochondrial biogenesis in aging-related diseases, and further illustrated the role of the signaling events between SIRT3 and mitochondrial biogenesis in the pathological process of aging-related diseases.
    • FullText(HTML)

  • A research based on population showed that the aging population is gradually increasing throughout the world[1–2]. However, there is a general physical and functioning decline with aging. Aging is an independent risk factor for diseases. Most common aging-related diseases include Parkinson's disease (PD), Alzheimer's disease (AD), type 2 diabetes mellitus (T2DM), cardiovascular disease, and cancer[2–3].

    Mitochondria, a major source of energy, are important organelles to fuel the human body's functions. Thereby, mitochondrial dysfunction is viewed as a potential regulator of the aging process[4]. Although plenty of factors, including abnormal mitochondrial quality control and aging[4], contribute to mitochondrial dysfunction, our attention is paid to mitochondrial biogenesis, yielding new mitochondria in response to various stress. Besides, mitochondrial dynamics will be discussed briefly.

    Mitochondrial function is modulated by a series of enzymes, the majority of which are also deacetylated by sirtuin 3 (SIRT3). SIRT3 targets many substrates controlling mitochondrial biogenesis through lysine deacetylation and modulates important cellular functions such as mitochondrial sugar, fat, and amino acid metabolism as well as reactive oxygen species (ROS) production and clearance[5].

    This review summarizes recent research on mitochondrial biogenesis and SIRT3, further illustrating the effects of SIRT3 on mitochondrial biogenesis in aging-related diseases.

    Sirtuins are a family of NAD+‐dependent histone deacetylases/mono-ADP-ribosyl transferase enzymes (SIRT1–SIRT7) and highly conserved in both bacteria and humans during the evolution[6–7]. Sirtuins have been reported to regulate a wide variety of biological processes such as metabolism, mitochondria homeostasis, genomic stability, DNA repair, ROS homeostasis, and aging[8–9]. SIRT3 is primarily localized in the mitochondria and functions as a major mitochondrial deacetylase that targets a growing number of substrates involved in metabolic homeostasis, mitochondrial dynamics, mitochondrial unfolded protein response, and oxidative stress[8]. In addition, SIRT3 protein is highly expressed in the brain, heart, liver, and brown adipose tissue[10]. SIRT3 controls global mitochondrial lysine acetylation level, and the sum of acetyl modifications are critical for these biological processes[10]. For instance, SIRT3 deacetylates numerous mitochondrial metabolic enzymes such as isocitrate dehydrogenase and malate dehydrogenase in the tricarboxylic acid cycle[11], complex Ⅰ, complex Ⅱ, and complex Ⅲ in the electron transport chain[12], and long-chain acyl-CoA dehydrogenase involved in the fatty acid oxidation pathway[13]. SIRT3 regulates these biosynthetic pathways involved in glucose and lipid metabolism and provides adequate energy to cells or tissues. SIRT3 deacetylates enzymes related to cellular anti-oxidative defense capacity, like superoxide dismutase 2 (SOD2) associated with ROS homeostasis[14], to prevent excessive ROS accumulation. SIRT3 can also stimulate the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) controlling mitochondrial biogenesis via adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) pathway to maintain mitochondrial quality and quantity[15]. Accordingly, SIRT3 is essential for sustaining anti-oxidative system, mitochondrial integrity, and normal mitochondrial function as the basis of physiological processes.

    It is well known that SIRT3 is strongly involved in the aging process. Subsequent genetic studies found the relationship between single nucleotide polymorphisms (SNPs) of the SIRT3 gene and longevity[16–17]. Three types of SNPs occurring in SIRT3 (G477T, variable number tandem repeat and V208I) have been discovered in human and SIRT3-knockout mice, and they can modify human health and lifespan[16,18–19].

    Upregulated SIRT3 increases energy generation to meet high energy demand during calorie restriction (CR), fasting, and exercise[17]. Accumulating evidence confirms that SIRT3 attenuation or ablation accelerates the development of aging-related diseases, including cancers, metabolic syndromes, cardiovascular diseases, and neurodegenerative diseases[12,20–21]. For example, SIRT3 protects dopaminergic neurons from degeneration and necrosis by regulating mitochondrial quality control, reducing mitochondrial oxidative stress, and downregulating α-synuclein (α-syn) in PD[21–24]. FOXO3 deacetylated by SIRT3 can maintain a balance between mitochondrial fission/fusion by inducing a series of FOXO3-dependent genes expression[25]. This process is beneficial in delaying the progression of PD. In response to stress situations, Ku70 is deacetylated by SIRT3, then binds to Bax, which protects cardiomyocyte against apoptosis induced by Bax[26]. SIRT3 was indicated to inhibit p53 activity, rescuing cells from apoptosis[27]. In PTEN-deficient cells, p53 at lysines 320 and 382 is modified by SIRT3, deteriorating the condition of non-small cell lung cancer[28]. Conversely, overexpression of SIRT3 in human glioma cells can promote tumor progression through Ku70-BAX interaction[29].

    Mitochondrial biogenesis is a complex process of mitochondrial growth and division. It requires the synthesis of proteins encoded by nuclear and mitochondrial (mt) DNA, besides the biogenesis of new organellar structures[30–31]. The nuclear genome encodes enormous mitochondrial enzymes and proteins, thus regulating transcriptional networks[32]. The mitochondrial DNA (mtDNA) is responsible for essential components of the electron transport chain as well as all rRNAs and tRNAs[33–34]. Biological processes, including transcription and replication from both nuclear and mtDNA, must be coordinated with each other to generate new mitochondrion in response to high-demand for energy[35] (Fig. 1).

    Figure  1.  Regulators of mitochondrial biogenesis.
    Mitochondrial biogenesis is a complex biological process, requiring cooperation with nuclear and mtDNA to generate enormous mitochondrial enzymes and proteins. Besides, mitochondrial biogenesis is regulated by plenty of external factors and internal molecules. CR: caloric restriction; PGC1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; TFAM: mitochondrial transcription factor A; mtDNA: mitochondrial DNA; AMPK: adenosine 5′-monophosphate (AMP)-activated protein kinase; NO: nitric oxide; SIRT1: sirtuin 1; SIRT3: sirtuin 3; ERRα: estrogen-related receptor alpha; CAMP: cyclic adenosine monophosphate; NRF1/2: nuclear respiratory factor 1/2.
    DownLoad: Full-Size Img PowerPoint

    It is well known that PGC1α is a primary regulator of mitochondrial biogenesis through activating nuclear respiratory factors (NRFs) and nuclear receptor subfamily (e.g., estrogen-related receptor alpha [ERRα]), expressing in tissues and organs with high-energy-requirements[35–36]. Because they regulate the expression of mitochondrial respiratory subunits and mitochondrial transcription factors including mitochondrial transcription factor A (TFAM) and mitochondrial transcription factor B (mtTFB) isoform genes[37]. These genes drive the transcription and replication of mtDNA. PGC1α drives multiple transcription factors (NRFs, ERRα, etc.), thus creating new mitochondria in response to various stress conditions[38].

    The regulation of mitochondrial biogenesis is affected by multiple internal and external factors through PGC1α[39]. Because PGC1α, one member of the transcriptional coactivators family, controls various aspects of mitochondrial biogenesis, including initiation of respiratory chain and fatty acid oxidation genes, an increase of mitochondrial number, and augmentation of mitochondrial respiratory capacity[33]. At the level of molecule, factors involved in activation of PGC1α include nitric oxide, AMPK, CREB, SIRT1, NRF-1and NRF-2[39–40]. However, RIP140 and p160 myb binding protein take part in the inhibition of PGC1α and thus suppress mitochondrial biogenesis[39]. At the level of the organism, hormones also influence mitochondrial biogenesis. Under oxidative stress, the thyroid hormone triiodothyronine can drive mitochondrial biogenesis and respiration process in various tissues of mouse[41–43], and steroid hormones stimulate production of mitochondrial proteome[39]. Hormones are capable of controlling mitochondrial biogenesis by affecting PPARGC1A level[38]. Besides, physiological environment changes are also reported to modulate mitochondrial biogenesis such as exercise, CR, hypoxia, stress, and temperature[40], and such observations were shown in rats and humans[44–45].

    In addition to mitochondrial biogenesis, mitochondrial fission (mito-fission) is a process in which mitochondria are broken up into smaller fragments, thereby producing two daughter mitochondria to increase mitochondrial mass during cell self-renewal[46]. During mito-fission, the damaged mitochondrion is removed by mitophagy, whereas the healthy one steps into the next phase, which is mitochondrial biogenesis[47]. Mito-fission is launched by endoplasmic reticulum (ER). Because once ER contacts with mitochondria, the sites at which dynamin-related protein 1 (DRP1) is recruited and assembles will be established[48]. DRP1, cutting the inner and outer membranes, also recruits some proteins aiding in splitting into two segments. Those proteins consist of mitochondrial receptor protein 1 (Fis1), mitochondrial fission factor (Mff), and mitochondrial dynamic proteins (MIDs)[47,49–50]. When cells are exposed to stresses, mito-fission bears the responsibility to maintain mitochondrial network functioning properly and promotes mitochondrial trafficking through segregating defective mitochondria and preserving the normal one[50].

    Facilitating mitochondrial biogenesis would be advantageous in many disease models, but once the balance of mitochondrial dynamics (mito-fission, mitophagy, and mitochondrial biogenesis) is destroyed, excessive mitochondrial biogenesis is detrimental to cells for extreme oxygen consumption[38].

    Aging brings a general decline in physiological functions. This process is featured by mitochondrial decay and decrease of oxidative phosphorylation (OXPHOS) capacity, along with changes in mitochondrial morphology and mitochondrial content (number and protein levels)[51]. Defective mitochondria, a hallmark of cellular aging, include malfunction of mitochondrial biogenesis, abnormal mitochondrial dynamics and trafficking, aberrant autophagy function, and transcriptional dysregulation[52–53]. The ability of mitochondrial biogenesis is in slow and progressive decline with age. Hence, mitochondrial biogenesis has been viewed as a target for delaying aging and extending lifespan[35,53–54]. Mitochondrial biogenesis, a self-renewal route, aims to generate new mitochondria from the existing one, in order to meet energy requirements and maintain the dynamic circulation of mitochondria through collaborating with mitochondrial autophagy[55]. Therefore, mitochondrial biogenesis plays an important role in maintaining homeostasis of the mitochondrial mass and function, malfunction of which is associated with aging, neurodegenerative diseases, metabolic diseases, and cancers[56].

    Tremendous efforts have been made to discover the role of mitochondrial biogenesis-related proteins and genes under pathological condition. Accumulative literature has reported that mtDNA deletion, mutation and damage result in mitochondrial dysfunction among different tissues or within the same tissue, eventually responsible for aging and age-related neurodegenerative diseases[57–58]. The accumulation of mtDNA mutations triggers neuronal loss in the substantia nigra of patients with PD or rat PD models[59–60], and negatively affects neuronal mitochondrial energy and synapse in the frontal cortex and hippocampus of AD patients[61]. Substantial evidence similarly shows that mtDNA damage is closely related to Huntington's disease (HD)[53,62–63].

    In another way, enhancement of mtDNA repair alleviates lung endothelial barrier dysfunction induced by donation after circulatory death related ischemia-reperfusion injury[64]. mtDNA copy number (mtDNAcn), regulated by transcriptional and translational factors, represents the mitochondrial abundance within a cell and varies with cellular energy requirement[65]. Alternations in mtDNAcn are associated with both increased and decreased disease burdens[51]. Some researchers hold the view that the upregulation of mtDNAcn due to overexpression of TFAM prolongs lifespan in the mouse suffering from mitochondrial diseases or myocardial infarction[66–67]. On the contrary, increased mtDNAcn negatively impacts the replication and transcription of mitochondrial proteins, accompanied by nucleoid enlargement[68]. These changes harm mitochondrial functions.

    In brief, damaged mitochondrial biogenesis contributes to an accumulation of old or dysfunctional mitochondria and the progression of various diseases.

    At the subcellular level, SIRT3 mainly localizes in mitochondria and deacetylates many mitochondrial metabolic proteins, and such observation was identified by mass spectrometry[69]. Likewise, mitochondrial metabolism such as fatty acid metabolism, glycolysis, and the tricarboxylic acid cycle is rich in acetylated proteins. SIRT3 plays a major role in sustaining mitochondrial bioenergetics. Thus, the pathway of SIRT3 and mitochondrial biogenesis is activated to maintain normal mitochondrial function and protect cell from death under pathological condition. In this part, we reviewed mitochondrial biogenesis with SIRT3 in three major aging-related diseases: cardiovascular diseases, neurodegenerative diseases, and T2DM. Additionally, the role of mitochondrial dynamics in the course of these diseases was summarized (Fig. 2 and Fig. 3).

    Figure  2.  Interaction between SIRT3 and PGC1α in neurodegenerative diseases.
    PGC1α/SIRT3 axis exerts a neuroprotective role in neurodegenerative diseases through maintaining normal mitochondrial function, ROS balance, and energy production. Impaired mitochondrial fusion/fission cycle is also a key component in the pathogenesis of neurodegenerative diseases. PGC1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; SIRT3: sirtuin 3; mtDNAcn: mtDNA copy number; ROS: reactive oxygen species; SOD2: superoxide dismutase 2; UCP-2: uncoupling protein 2.
    DownLoad: Full-Size Img PowerPoint
    Figure  3.  Interaction between SIRT3 and PGC1α in cardiovascular diseases and type 2 diabetes mellitus.
    A: Under external stress, cardiovascular system is sheltered by mitochondrial biogenesis regulated by SIRT3 and mitochondrial fusion controlled by PGC1α. B: Hyperglycemia disrupted PGC1α/SIRT3 axis, along with OXPHOS and a ROS defense system decline. Besides, abnormal mitochondrial dynamics are involved in the progression of the two diseases. PGC1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; SIRT1: sirtuin 1; SIRT3: sirtuin 3; mtDNAcn: mtDNA copy number; ROS: reactive oxygen species; IRS: insulin receptor substrate; Mfn2: mitofusin 2; OXPHOS: oxidative phosphorylation; EC: endothelial cells.
    DownLoad: Full-Size Img PowerPoint

    Neurodegenerative diseases include AD, PD, HD, and amyotrophic lateral sclerosis (ALS). Featured by high-energy demand, neurons are vulnerable to oxidative stressors. Thus, the decrease of ATP level will result in neuronal death in patients with neurodegenerative diseases[70]. Mitochondrial malfunction and oxidative damage are pivotal contributors to the development of neurodegenerative diseases[71–73].

    The mtDNA or nuclear DNA mutations are reported to cause diseases related to neuronal degeneration[71]. The mtDNA replication machinery is more error-prone than that of genomic DNA, because the mtDNA polymerase lacks the function of proofreading[34,74]. Besides, DNA repair system is less reliable. The mtDNA damage can impair respiratory chain protein synthesis, reduce the efficiency of energy production and overproduce ROS. An increase in ROS impairs mtDNA in the same manner and misfolds proteins, vice versus[75]. These processes are related to mitochondrial dysfunction, eventually accelerating the development of diseases such as HD, AD, ALS, and hypertension[72,74]. However, SIRT3 possesses the ability to repair mtDNA damage, preserve mitochondrial function and protect apoptotic cell against death through deacetylating a variety of protein targets. These proteins consist of endonuclease Ⅷ-like 1, endonuclease Ⅷ-like 1 (NEIL2), 8-oxoguanine-DNA glycosylase 1 (OGG1)[76], mutY DNA glycosylase (MUTYH), apurinic/apyrimidinic endonuclease (APE1), and DNA ligase 3 (LIG3)[77], which modulate the activity of mtDNA base excision repair (BER), consequently taking charge of removing damaged bases. A large body of findings support that mtDNA repair machinery is impaired in neurodegenerative disorders[78–80]. In Caenorhabditis elegans PD models, incomplete BER results in genomic stress, promoting neuronal loss and further driving pathological process of age-related neurodegeneration[81]. Evidence supporting a critical role for DNA repair deficiencies in AD demonstrated that compromised DNA repair is a driving force of neuronal dysfunction and loss, because of damaged mitophagy, metabolic disturbance, and energy deprivation[82]. Research in ALS patients confirmed the perspective that altered mtDNA (mtDNA mutations and deletions) was observed in spinal neurons of ALS, driving synaptic dysfunction and facilitating motor neuron degeneration[83]. Altogether, studies concerning mtDNA alternations or ineffective BER demonstrate they have tight connection with neurodegenerative diseases.

    SIRT3 and PGC-1α play a neuroprotective role in ALS model through preventing mitochondrial fragmentation and neuronal cell apoptosis[84]. SIRT3 is beneficial to maintaining ROS balance between production and clearance, overexpression of which suppresses ROS accumulation. PGC1α, strongly detected in tissues with high requirement for energy, not only induces antioxidant defense gene expression such as SOD2 and uncoupling protein 2 to stop oxidative damage and mitochondrial destruction[85], but also modulates SIRT3 expression to achieve ROS homeostasis. In mutant SOD1 mice, motor neurons were found to develop degeneration due to aberrated mitochondria aggregation in neuronal axons and dendrites[72]. Knockout of SIRT3 suppresses antioxidant gene expression, leading to mitochondrial disequilibrium of antioxidant defense controlled by PGC1α[84]. Additionally, research in neuro-2a cell and SIRT3-knockout mice demonstrated that loss of SIRT3 had a deleterious effect on SOD2 and ATP synthase β acetylation levels targeting functional sites (SOD2-K130 and ATP synthase b-K485), critical for the regulation of ROS and ATP levels[86]. ROS aggregation and reduction in ATP are responsible for neuronal death in PD mice. Another insight is that PGC1a is a regulator of SIRT3 through interacting with ERRα to protect against dopaminergic neuronal death, a hallmark of PD[86].

    The imbalance of mitochondrial dynamics is a key component in the pathogenesis of neurodegenerative diseases such as PD and AD[87–88]. In PD, α-syn aggregation in the neuron is capable to perturb the cycle of mitochondrial fusion and fission because of its deleterious effect on mitochondrial associated proteins including mitofusin 1 and 2 (Mfn1/2), DRP1, and MFF, correlative with an increase in aberrant mitochondria and inefficiency of neuronal signaling[89–90]. Mitophagy, functioning as degrading damaged mitochondria, is also under the adverse influence of α-syn in PD[88]. Interestingly, SIRT3 depends on optic atrophy 1 (OPA1), a mitochondrial fusion regulator, to maintain normal mitochondrial dynamics, ultimately preventing cell apoptosis via the effect on cytochrome c translocation and mitochondrial respiratory efficacy[91]. Recently, research in the HD model reveals that upregulated SIRT3 contributes to mitochondrial fusion, rather than fission, leading to remodeled mitochondrial function, dynamics, and distribution in neural cells, further exerting neuroprotective effect. Decline in DRP1 and Fis1 levels caused by SIRT3 suppresses mitochondrial fission and biogenesis, and it means that mitochondrial mass isn't affected in HD[92]. Overall, SIRT3 has certain impacts on neurodegenerative diseases through the modulation of mitochondrial dynamics.

    A small number of mitochondria exist in cardiomyocytes, one of the highest energy consuming cell types[93–94]. Not surprisingly, mitochondria in the function of vascular endothelial cells (VECs) as a metabolic signaling regulator triggering cell proliferation or apoptosis instead of energy supply[93]. Aberrant mitochondrial function is a contributing factor to endothelial dysfunction, responsible for cardiovascular diseases such as cardiac hypertrophy and atherosclerosis.

    SIRT3 plays a protective role in myocardial cells via different signaling pathways to promote mitochondrial biogenesis. SIRT3 protects cardiomyocytes from ischemia reperfusion injury by preventing mitochondria mediated apoptosis, and this effect has been related to the activation of the AMPK pathway[15]. One explanation is that AMPK, an energy sensor of cells, drives mitochondrial biogenesis machinery in response to energy demand[40]. This viewpoint was supported by research in H9c2 cell, overexpression of SIRT3 induced corresponding changes in expression of mtDNA encoded genes, SOD2 expression and activity through the AMPKα-PGC1α axis, contributing to mitochondrial biogenesis and protecting myocardial cells[95]. Another function of PGC1α in VECs is to modulate several antioxidant enzymes, strengthening ROS defenses[96]. Furthermore, PGC1α controls some genes expression related to fatty acid oxidation, the tricarboxylic acid cycle, electron transport chain, and oxidative phosphorylation[97], promoting vascular endothelial growth factor (VEGF) expression[92] and protects against apoptosis via the effect of 15-hydroxyeicosatetraenoic acid[98]. This process mentioned above accelerates VEC proliferation and activates vessel sprouting in response to environmental stimulus (e.g., CR and hypoxia)[93].

    Respiratory chain generates amounts of cellular energy, along with free radicals and ROS as by-products. Minimal ROS are conducive to signal transduction in physiological surroundings, whereas elevated ROS damages the adjacent cell structures, and alters DNA, proteins, and other molecules, further causing cell death[34]. It's well documented that excessive mitochondrial ROS give rise to VEC dysfunction, leading to formation of atherogenesis and cardiac hypertrophy[34,74]. Mitochondria-targeted esculetin-induced SIRT3, not SIRT1 overexpression, a new lipoxygenase inhibitor, protects endothelial cells from death through AMPK-mediated nitric oxide pathway, thus attenuating plaque formation[99]. Another perspective is that SIRT1 and SIRT3 cooperate to drive the antiaging effects under CR condition[100]. Increased expression of SIRT1 deacetylates and activates PGC1α in response to nutrient limitation, which further reduces ROS production, and promotes antioxidant environment through coactivating transcription of SIRT3[100–101]. This relationship is beneficial for longevity because of elevated mitochondrial biogenesis and ROS detoxification.

    Therefore, mitochondrial dynamics play a critical role in VECs. Fusion proteins such as mfn1, mfn2, and OPA1 are associated with VEGF-mediated angiogenesis and angiogenic function[102–103]. The Mfn2 unregulated by PGC1α and PGC1β can promote mitochondrial fusion[104]. After knocking out the mfn2 gene in the heart of the mouse, calcium (Ca2+) fails to transfer from sarcoplasmic reticulum to mitochondria, followed by disrupted Ca2+ signaling, and diminished cardiac contractility function[105]. Evidence indicates that lacking cardiac-specific mfn2 undermines cellular autophagy and impairs mitochondrial network function, ultimately leading to aberrant left ventricular function[106].

    T2DM is featured by deficient mitochondrial function and ROS. SIRT3 deacetylates and modifies several mitochondrial protease activities to manage mitochondrial functions and maintain redox homeostasis. The reduction of SIRT3 function contributes to the development of insulin resistance (IR), and hallmark of the pathogenesis of T2DM[107–108]. Evidence from experiment in cultured human endothelial cells demonstrated that SIRT3 deficiency is implicated in endothelial IR because of a drop in phosphorylation of Akt and endothelial nitric oxide synthase[109]. Similarly, overexpression of SIRT3 ameliorates negative effect of pancreatic β-cell involving malfunction and apoptosis induced by palmitate[110]. β-cell dysfunction is related to dysregulation of insulin synthesis and insulin deficiency, further leading to hyperglycemia[111–112]. Hyperglycemia in turn promotes mitochondria fragmentation, and increases ROS production[113].

    In pre-diabetic model, the researcher found that PGC1α/SIRT3 axis of testis was disrupted, accompanied by mtDNAcn decline[114]. PGC1α and Sirt3 are implicated in various biological processes such as mitochondrial biogenesis, functional OXPHOS, and an active ROS defense system[101]. The impaired PGC1α/SIRT3 axis compromises respiratory capacity, and promotes oxidative stress. Additionally, mitochondrial dynamics is not only the link between impaired mitochondrial function and IR, but also implicated in the development of T2D[115–117]. Diabetes susceptible cybrid cell model has demonstrated that IR is a consequence of abnormal mitochondrial dynamics, because upregulating Mfn1/Mfn2 genes and depressing DRP1/Fis1 can remodel mitochondrial network, repairing the IR signaling[118]. According to some viewpoints, both insulin signaling and insulin sensitivity are manipulated by Mfn2. In Mfn2 KO mouse, glucose tolerance and IRS-Akt pathway were impaired, whereas hepatic glucose production was enhanced[115]. Reduced Mfn2 expression was also found in T2D patients' muscles.

    This review summarizes the involvement of SIRT3 and mitochondrial biogenesis in aging-related diseases. Based on SIRT3 regulation of mitochondrial function, we reviewed that there are intersecting signaling pathways between SIRT3 and mitochondrial biogenesis such as AMPK-PGC1α axis, SIRT1-PGC1α axis, and PGC1α/SIRT3 axis in the development of aging-related diseases including neurodegenerative diseases[19], cardiovascular diseases[12] and T2DM[114]. Impaired mitochondrial dynamics such as mitochondrial fusion and fission participate in the process of aging-related disease progression as well. Notably, manipulation of SIRT3, mitochondrial biogenesis, and mitochondrial dynamics offers novel therapeutic options for these aging-related diseases. However, other aspects of mitochondrial dysfunction such as abnormal mitochondrial quality control, mitochondrial homeostasis imbalance, and mitophagy dysfunction also account for aging-related disease progression and development. Thus, future investigations on SIRT3-mediated mitochondrial function may aid in providing new pathways during the aging process.

    None.

    None.

    CLC number: R592, Document code: A

    The authors reported no conflict of interests.

    • References (118)
  • [1]
    Ferrucci L, Giallauria F, Guralnik JM. Epidemiology of aging[J]. Radiol Clin North Am, 2008, 46(4): 643–652. doi: 10.1016/j.rcl.2008.07.005
    [2]
    Jaul E, Barron J. Age-related diseases and clinical and public health implications for the 85 years old and over population[J]. Front Public Health, 2017, 5: 335. doi: 10.3389/fpubh.2017.00335
    [3]
    Li Z, Zhang Z, Ren Y, et al. Aging and age-related diseases: from mechanisms to therapeutic strategies[J]. Biogerontology, 2021, 22(2): 165–187. doi: 10.1007/s10522-021-09910-5
    [4]
    Jang J, Blum A, Liu J, et al. The role of mitochondria in aging[J]. J Clin Invest, 2018, 128(9): 3662–3670. doi: 10.1172/JCI120842
    [5]
    Huang W, Huang Y, Huang R, et al. SIRT3 expression decreases with reactive oxygen species generation in rat cortical neurons during early brain injury induced by experimental subarachnoid hemorrhage[J]. Biomed Res Int, 2016, 2016: 8263926. doi: 10.1155/2016/8263926
    [6]
    Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity[J]. Biochem Biophys Res Commun, 1999, 260(1): 273–279. doi: 10.1006/bbrc.1999.0897
    [7]
    Almeida M, Porter RM. Sirtuins and FoxOs in osteoporosis and osteoarthritis[J]. Bone, 2019, 121: 284–292. doi: 10.1016/j.bone.2019.01.018
    [8]
    Jeong SM, Haigis MC. Sirtuins in cancer: a balancing act between genome stability and metabolism[J]. Mol Cells, 2015, 38(9): 750–758. doi: 10.14348/molcells.2015.0167
    [9]
    Bause AS, Haigis MC. SIRT3 regulation of mitochondrial oxidative stress[J]. Exp Gerontol, 2013, 48(7): 634–639. doi: 10.1016/j.exger.2012.08.007
    [10]
    Lombard DB, Alt FW, Cheng HL, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation[J]. Mol Cell Biol, 2007, 27(24): 8807–8814. doi: 10.1128/MCB.01636-07
    [11]
    Fu X, Li K, Niu Y, et al. The mTOR/PGC-1α/SIRT3 pathway drives reductive glutamine metabolism to reduce oxidative stress caused by ISKNV in CPB cells[J]. Microbiol Spectr, 2022, 10(1): e0231021. doi: 10.1128/spectrum.02310-21
    [12]
    Wu J, Zeng Z, Zhang W, et al. Emerging role of SIRT3 in mitochondrial dysfunction and cardiovascular diseases[J]. Free Radic Res, 2019, 53(2): 139–149. doi: 10.1080/10715762.2018.1549732
    [13]
    Chen T, Liu J, Li N, et al. Mouse SIRT3 attenuates hypertrophy-related lipid accumulation in the heart through the deacetylation of LCAD[J]. PLoS One, 2015, 10(3): e0118909. doi: 10.1371/journal.pone.0118909
    [14]
    Liu J, Li D, Zhang T, et al. SIRT3 protects hepatocytes from oxidative injury by enhancing ROS scavenging and mitochondrial integrity[J]. Cell Death Dis, 2017, 8(10): e3158. doi: 10.1038/cddis.2017.564
    [15]
    Xin T, Lu C. SirT3 activates AMPK-related mitochondrial biogenesis and ameliorates sepsis-induced myocardial injury[J]. Aging, 2020, 12(16): 16224–16237. doi: 10.18632/aging.103644
    [16]
    Bellizzi D, Rose G, Cavalcante P, et al. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages[J]. Genomics, 2005, 85(2): 258–263. doi: 10.1016/j.ygeno.2004.11.003
    [17]
    Kincaid B, Bossy-Wetzel E. Forever young: SIRT3 a shield against mitochondrial meltdown, aging, and neurodegeneration[J]. Front Aging Neurosci, 2013, 5: 48. doi: 10.3389/fnagi.2013.00048
    [18]
    Rose G, Dato S, Altomare K, et al. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly[J]. Exp Gerontol, 2003, 38(10): 1065–1070. doi: 10.1016/S0531-5565(03)00209-2
    [19]
    Hirschey MD, Shimazu T, Jing E, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome[J]. Mol Cell, 2011, 44(2): 177–190. doi: 10.1016/j.molcel.2011.07.019
    [20]
    McDonnell E, Peterson BS, Bomze HM, et al. SIRT3 regulates progression and development of diseases of aging[J]. Trends Endocrinol Metab, 2015, 26(9): 486–492. doi: 10.1016/j.tem.2015.06.001
    [21]
    Meng H, Yan W, Lei Y, et al. SIRT3 regulation of mitochondrial quality control in neurodegenerative diseases[J]. Front Aging Neurosci, 2019, 11: 313. doi: 10.3389/fnagi.2019.00313
    [22]
    Gleave JA, Arathoon LR, Trinh D, et al. Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism[J]. Neurobiol Dis, 2017, 106: 133–146. doi: 10.1016/j.nbd.2017.06.009
    [23]
    Park JH, Burgess JD, Faroqi AH, et al. Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway[J]. Mol Neurodegener, 2020, 15(1): 5. doi: 10.1186/s13024-019-0349-x
    [24]
    Huang D, Liu M, Jiang Y. Mitochonic acid-5 attenuates TNF-α-mediated neuronal inflammation via activating Parkin-related mitophagy and augmenting the AMPK-Sirt3 pathways[J]. J Cell Physiol, 2019, 234(12): 22172–22182. doi: 10.1002/jcp.28783
    [25]
    Tseng AHH, Shieh SS, Wang DL. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage[J]. Free Radic Biol Med, 2013, 63: 222–234. doi: 10.1016/j.freeradbiomed.2013.05.002
    [26]
    Sundaresan NR, Samant SA, Pillai VB, et al. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70[J]. Mol Cell Biol, 2008, 28(20): 6384–6401. doi: 10.1128/MCB.00426-08
    [27]
    Chen J, Wang A, Chen Q. SirT3 and p53 deacetylation in aging and cancer[J]. J Cell Physiol, 2017, 232(9): 2308–2311. doi: 10.1002/jcp.25669
    [28]
    Xiong Y, Wang L, Wang S, et al. SIRT3 deacetylates and promotes degradation of P53 in PTEN-defective non-small cell lung cancer[J]. J Cancer Res Clin Oncol, 2018, 144(2): 189–198. doi: 10.1007/s00432-017-2537-9
    [29]
    Luo K, Huang W, Tang S. Sirt3 enhances glioma cell viability by stabilizing Ku70-BAX interaction[J]. Onco Targets Ther, 2018, 11: 7559–7567. doi: 10.2147/OTT.S172672
    [30]
    Liu H, He Z, Germič N, et al. ATG12 deficiency leads to tumor cell oncosis owing to diminished mitochondrial biogenesis and reduced cellular bioenergetics[J]. Cell Death Differ, 2020, 27(6): 1965–1980. doi: 10.1038/s41418-019-0476-5
    [31]
    Wenz T. Regulation of mitochondrial biogenesis and PGC-1α under cellular stress[J]. Mitochondrion, 2013, 13(2): 134–142. doi: 10.1016/j.mito.2013.01.006
    [32]
    Dorn II GW, Vega RB, Kelly DP. Mitochondrial biogenesis and dynamics in the developing and diseased heart[J]. Genes Dev, 2015, 29(19): 1981–1991. doi: 10.1101/gad.269894.115
    [33]
    Scarpulla RC, Vega RB, Kelly DP. Transcriptional integration of mitochondrial biogenesis[J]. Trends Endocrinol Metab, 2012, 23(9): 459–466. doi: 10.1016/j.tem.2012.06.006
    [34]
    Peng W, Cai G, Xia Y, et al. Mitochondrial dysfunction in atherosclerosis[J]. DNA Cell Biol, 2019, 38(7): 597–606. doi: 10.1089/dna.2018.4552
    [35]
    Wang J, Toan S, Zhou H. Mitochondrial quality control in cardiac microvascular ischemia-reperfusion injury: new insights into the mechanisms and therapeutic potentials[J]. Pharmacol Res, 2020, 156: 104771. doi: 10.1016/j.phrs.2020.104771
    [36]
    Wang J, Toan S, Zhou H. New insights into the role of mitochondria in cardiac microvascular ischemia/reperfusion injury[J]. Angiogenesis, 2020, 23(3): 299–314. doi: 10.1007/s10456-020-09720-2
    [37]
    Scarpulla RC. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator[J]. Ann N Y Acad Sci, 2008, 1147: 321–334. doi: 10.1196/annals.1427.006
    [38]
    Zhu J, Wang KZ, Chu CT. After the banquet: mitochondrial biogenesis, mitophagy, and cell survival[J]. Autophagy, 2013, 9(11): 1663–1676. doi: 10.4161/auto.24135
    [39]
    López-Lluch G, Irusta PM, Navas P, et al. Mitochondrial biogenesis and healthy aging[J]. Exp Gerontol, 2008, 43(9): 813–819. doi: 10.1016/j.exger.2008.06.014
    [40]
    Jornayvaz FR, Shulman GI. Regulation of mitochondrial biogenesis[J]. Essays Biochem, 2010, 47: 69–84. doi: 10.1042/bse0470069
    [41]
    Yau WW, Singh BK, Lesmana R, et al. Thyroid hormone (T3) stimulates brown adipose tissue activation via mitochondrial biogenesis and MTOR-mediated mitophagy[J]. Autophagy, 2019, 15(1): 131–150. doi: 10.1080/15548627.2018.1511263
    [42]
    Lesmana R, Sinha RA, Singh BK, et al. Thyroid hormone stimulation of autophagy is essential for mitochondrial biogenesis and activity in skeletal muscle[J]. Endocrinology, 2016, 157(1): 23–38. doi: 10.1210/en.2015-1632
    [43]
    Sinha RA, Singh BK, Zhou J, et al. Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling[J]. Autophagy, 2015, 11(8): 1341–1357. doi: 10.1080/15548627.2015.1061849
    [44]
    Kang C, Lim W. Data on mitochondrial function in skeletal muscle of old mice in response to different exercise intensity[J]. Data Brief, 2016, 7: 1519–1523. doi: 10.1016/j.dib.2016.04.043
    [45]
    Holloszy JO. Biochemical adaptations in muscle. Effects of exercise on mitochondrial oxygen uptake and respiratory enzyme activity in skeletal muscle[J]. J Biol Chem, 1967, 242(9): 2278–2282. doi: 10.1016/S0021-9258(18)96046-1
    [46]
    Tristan C, Shahani N, Sedlak TW, et al. The diverse functions of GAPDH: views from different subcellular compartments[J]. Cell Signal, 2011, 23(2): 317–323. doi: 10.1016/j.cellsig.2010.08.003
    [47]
    Grasso D, Zampieri LX, Capelôa T, et al. Mitochondria in cancer[J]. Cell Stress, 2020, 4(6): 114–146. doi: 10.15698/cst2020.06.221
    [48]
    Morris MC, Evans DA, Tangney CC, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline[J]. Arch Neurol, 2006, 63(8): 1085–1088. doi: 10.1001/archneur.63.8.1085
    [49]
    Chan DC. Fusion and fission: interlinked processes critical for mitochondrial health[J]. Annu Rev Genet, 2012, 46: 265–287. doi: 10.1146/annurev-genet-110410-132529
    [50]
    Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress[J]. Science, 2012, 337(6098): 1062–1065. doi: 10.1126/science.1219855
    [51]
    Filograna R, Mennuni M, Alsina D, et al. Mitochondrial DNA copy number in human disease: the more the better?[J]. FEBS Lett, 2021, 595(8): 976–1002. doi: 10.1002/1873-3468.14021
    [52]
    Cortes CJ, La Spada AR. The many faces of autophagy dysfunction in Huntington's disease: from mechanism to therapy[J]. Drug Discov Today, 2014, 19(7): 963–971. doi: 10.1016/j.drudis.2014.02.014
    [53]
    Bečanović K, Asghar M, Gadawska I, et al. Age-related mitochondrial alterations in brain and skeletal muscle of the YAC128 model of Huntington disease[J]. npj Aging Mech Dis, 2021, 7(1): 26. doi: 10.1038/s41514-021-00079-2
    [54]
    Zhu P, Hu S, Jin Q, et al. Ripk3 promotes ER stress-induced necroptosis in cardiac IR injury: a mechanism involving calcium overload/XO/ROS/mPTP pathway[J]. Redox Biol, 2018, 16: 157–168. doi: 10.1016/j.redox.2018.02.019
    [55]
    Zhou H, Zhang Y, Hu S, et al. Melatonin protects cardiac microvasculature against ischemia/reperfusion injury via suppression of mitochondrial fission-VDAC1-HK2-mPTP-mitophagy axis[J]. J Pineal Res, 2017, 63(1): e12413. doi: 10.1111/jpi.12413
    [56]
    Popov LD. Mitochondrial biogenesis: an update[J]. J Cell Mol Med, 2020, 24(9): 4892–4899. doi: 10.1111/jcmm.15194
    [57]
    Kraytsberg Y, Kudryavtseva E, Mckee AC, et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons[J]. Nat Genet, 2006, 38(5): 518–520. doi: 10.1038/ng1778
    [58]
    Trifunovic A, Hansson A, Wredenberg A, et al. Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production[J]. Proc Natl Acad Sci U S A, 2005, 102(50): 17993–17998. doi: 10.1073/pnas.0508886102
    [59]
    Parkinson GM, Dayas CV, Smith DW. Increased mitochondrial DNA deletions in substantia nigra dopamine neurons of the aged rat[J]. Curr Aging Sci, 2014, 7(3): 155–160. doi: 10.2174/1874609808666150122150850
    [60]
    Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease[J]. Nat Genet, 2006, 38(5): 515–517. doi: 10.1038/ng1769
    [61]
    Coskun P, Beal M, Wallace D. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication[J]. Proc Natl Acad Sci U S A, 2004, 101(29): 10726–10731. doi: 10.1073/pnas.0403649101
    [62]
    Banoei MM, Houshmand M, Panahi MSS, et al. Huntington's disease and mitochondrial DNA deletions: event or regular mechanism for mutant huntingtin protein and CAG repeats expansion?![J]. Cell Mol Neurobiol, 2007, 27(7): 867–875. doi: 10.1007/s10571-007-9206-5
    [63]
    Acevedo-Torres K, Berríos L, Rosario N, et al. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease[J]. DNA Repair (Amst), 2009, 8(1): 126–136. doi: 10.1016/j.dnarep.2008.09.004
    [64]
    Tan YB, Pastukh VM, Gorodnya OM, et al. Enhanced mitochondrial DNA repair resuscitates transplantable lungs donated after circulatory death[J]. J Surg Res, 2020, 245: 273–280. doi: 10.1016/j.jss.2019.07.057
    [65]
    Laubenthal L, Hoelker M, Frahm J, et al. Mitochondrial DNA copy number and biogenesis in different tissues of early- and late-lactating dairy cows[J]. J Dairy Sci, 2016, 99(2): 1571–1583. doi: 10.3168/jds.2015-9847
    [66]
    Nishiyama S, Shitara H, Nakada K, et al. Over-expression of Tfam improves the mitochondrial disease phenotypes in a mouse model system[J]. Biochem Biophys Res Commun, 2010, 401(1): 26–31. doi: 10.1016/j.bbrc.2010.08.143
    [67]
    Ikeuchi M, Matsusaka H, Kang D, et al. Overexpression of mitochondrial transcription factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction[J]. Circulation, 2005, 112(5): 683–690. doi: 10.1161/CIRCULATIONAHA.104.524835
    [68]
    Ylikallio E, Tyynismaa H, Tsutsui H, et al. High mitochondrial DNA copy number has detrimental effects in mice[J]. Hum Mol Genet, 2010, 19(13): 2695–2705. doi: 10.1093/hmg/ddq163
    [69]
    Carrico C, Meyer JG, He W, et al. The mitochondrial acylome emerges: proteomics, regulation by sirtuins, and metabolic and disease implications[J]. Cell Metab, 2018, 27(3): 497–512. doi: 10.1016/j.cmet.2018.01.016
    [70]
    McNaught KSP, Jackson T, Jnobaptiste R, et al. Proteasomal dysfunction in sporadic Parkinson's disease[J]. Neurology, 2006, 66(10 S4): S37–S49. doi: 10.1212/wnl.66.10_suppl_4.s37
    [71]
    Beal MF. Mitochondria take center stage in aging and neurodegeneration[J]. Ann Neurol, 2005, 58(4): 495–505. doi: 10.1002/ana.20624
    [72]
    Manfredi G, Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS[J]. Mitochondrion, 2005, 5(2): 77–87. doi: 10.1016/j.mito.2005.01.002
    [73]
    Genin EC, Madji Hounoum B, Bannwarth S, et al. Mitochondrial defect in muscle precedes neuromuscular junction degeneration and motor neuron death in CHCHD10S59L/+ mouse[J]. Acta Neuropathol, 2019, 138(1): 123–145. doi: 10.1007/s00401-019-01988-z
    [74]
    Salnikova D, Orekhova V, Grechko A, et al. Mitochondrial dysfunction in vascular wall cells and its role in atherosclerosis[J]. Int J Mol Sci, 2021, 22(16): 8990. doi: 10.3390/ijms22168990
    [75]
    Papa L, Germain D. SirT3 regulates the mitochondrial unfolded protein response[J]. Mol Cell Biol, 2014, 34(4): 699–710. doi: 10.1128/MCB.01337-13
    [76]
    Cheng Y, Ren X, Gowda AS, et al. Interaction of Sirt3 with OGG1 contributes to repair of mitochondrial DNA and protects from apoptotic cell death under oxidative stress[J]. Cell Death Dis, 2013, 4(7): e731. doi: 10.1038/cddis.2013.254
    [77]
    Kabziński J, Walczak A, Mik M, et al. Sirt3 regulates the level of mitochondrial DNA repair activity through deacetylation of NEIL1, NEIL2, OGG1, MUTYH, APE1 and LIG3 in colorectal cancer[J]. Pol Przegl Chir, 2019, 92(1): 1–4. doi: 10.5604/01.3001.0013.5539
    [78]
    Yang JL, Weissman L, Bohr VA, et al. Mitochondrial DNA damage and repair in neurodegenerative disorders[J]. DNA Repair (Amst), 2008, 7(7): 1110–1120. doi: 10.1016/j.dnarep.2008.03.012
    [79]
    LeDoux SP, Druzhyna NM, Hollensworth SB, et al. Mitochondrial DNA repair: a critical player in the response of cells of the CNS to genotoxic insults[J]. Neuroscience, 2007, 145(4): 1249–1259. doi: 10.1016/j.neuroscience.2006.10.002
    [80]
    Weissman L, de Souza-pinto NC, Stevnsner T, et al. DNA repair, mitochondria, and neurodegeneration[J]. Neuroscience, 2007, 145(4): 1318–1329. doi: 10.1016/j.neuroscience.2006.08.061
    [81]
    SenGupta T, Palikaras K, Esbensen YQ, et al. Base excision repair causes age-dependent accumulation of single-stranded DNA breaks that contribute to Parkinson disease pathology[J]. Cell Rep, 2021, 36(10): 109668. doi: 10.1016/j.celrep.2021.109668
    [82]
    Wang H, Lautrup S, Caponio D, et al. DNA damage-induced neurodegeneration in accelerated ageing and Alzheimer's disease[J]. Int J Mol Sci, 2021, 22(13): 6748. doi: 10.3390/ijms22136748
    [83]
    Keeney PM, Bennett Jr JP. ALS spinal neurons show varied and reduced mtDNA gene copy numbers and increased mtDNA gene deletions[J]. Mol Neurodegener, 2010, 5: 21. doi: 10.1186/1750-1326-5-21
    [84]
    Song W, Song Y, Kincaid B, et al. Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1α[J]. Neurobiol Dis, 2013, 51: 72–81. doi: 10.1016/j.nbd.2012.07.004
    [85]
    Rius-Pérez S, Torres-Cuevas I, Millán I, et al. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism[J]. Oxid Med Cell Longev, 2020, 2020: 1452696. doi: 10.1155/2020/1452696
    [86]
    Zhang X, Ren X, Zhang Q, et al. PGC-1α/ERRα-sirt3 pathway regulates DAergic neuronal death by directly deacetylating SOD2 and ATP synthase β[J]. Antioxid Redox Signal, 2016, 24(6): 312–328. doi: 10.1089/ars.2015.6403
    [87]
    Lim KL, Ng XH, Grace LGY, et al. Mitochondrial dynamics and Parkinson's disease: focus on parkin[J]. Antioxid Redox Signal, 2012, 16(9): 935–949. doi: 10.1089/ars.2011.4105
    [88]
    Valdinocci D, Simões RF, Kovarova J, et al. Intracellular and intercellular mitochondrial dynamics in Parkinson's disease[J]. Front Neurosci, 2019, 13: 930. doi: 10.3389/fnins.2019.00930
    [89]
    Wang X, Becker K, Levine N, et al. Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration[J]. Acta Neuropathol Commun, 2019, 7(1): 41. doi: 10.1186/s40478-019-0696-4
    [90]
    Vijayakumaran S, Pountney DL. SUMOylation, aging and autophagy in neurodegeneration[J]. NeuroToxicology, 2018, 66: 53–57. doi: 10.1016/j.neuro.2018.02.015
    [91]
    Yi X, Guo W, Shi Q, et al. SIRT3-dependent mitochondrial dynamics remodeling contributes to oxidative stress-induced melanocyte degeneration in vitiligo[J]. Theranostics, 2019, 9(6): 1614–1633. doi: 10.7150/thno.30398
    [92]
    Naia L, Carmo C, Campesan S, et al. Mitochondrial SIRT3 confers neuroprotection in Huntington's disease by regulation of oxidative challenges and mitochondrial dynamics[J]. Free Radic Biol Med, 2021, 163: 163–179. doi: 10.1016/j.freeradbiomed.2020.11.031
    [93]
    Caja S, Enríquez JA. Mitochondria in endothelial cells: sensors and integrators of environmental cues[J]. Redox Biol, 2017, 12: 821–827. doi: 10.1016/j.redox.2017.04.021
    [94]
    Oldendorf WH, Cornford ME, Brown WJ. The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat[J]. Ann Neurol, 1977, 1(5): 409–417. doi: 10.1002/ana.410010502
    [95]
    Bugga P, Alam MJ, Kumar R, et al. Sirt3 ameliorates mitochondrial dysfunction and oxidative stress through regulating mitochondrial biogenesis and dynamics in cardiomyoblast[J]. Cell Signal, 2022, 94: 110309. doi: 10.1016/j.cellsig.2022.110309
    [96]
    Valle I, Álvarez-Barrientos A, Arza E, et al. PGC-1α regulates the mitochondrial antioxidant defense system in vascular endothelial cells[J]. Cardiovasc Res, 2005, 66(3): 562–573. doi: 10.1016/j.cardiores.2005.01.026
    [97]
    Leone TC, Kelly DP. Transcriptional control of cardiac fuel metabolism and mitochondrial function[J]. Cold Spring Harb Symp Quant Biol, 2011, 76: 175–182. doi: 10.1101/sqb.2011.76.011965
    [98]
    Li J, Zhang Y, Liu Y, et al. PGC-1α plays a major role in the anti-apoptotic effect of 15-HETE in pulmonary artery endothelial cells[J]. Respir Physiol Neurobiol, 2015, 205: 84–91. doi: 10.1016/j.resp.2014.10.015
    [99]
    Karnewar S, Vasamsetti SB, Gopoju R, et al. Mitochondria-targeted esculetin alleviates mitochondrial dysfunction by AMPK-mediated nitric oxide and SIRT3 regulation in endothelial cells: potential implications in atherosclerosis[J]. Sci Rep, 2016, 6: 24108. doi: 10.1038/srep24108
    [100]
    Bell EL, Guarente L. The SirT3 divining rod points to oxidative stress[J]. Mol Cell, 2011, 42(5): 561–568. doi: 10.1016/j.molcel.2011.05.008
    [101]
    Kong X, Wang R, Xue Y, et al. Sirtuin 3, a new target of PGC-1α, plays an important role in the suppression of ROS and mitochondrial biogenesis[J]. PLoS One, 2010, 5(7): e11707. doi: 10.1371/journal.pone.0011707
    [102]
    Lugus JJ, Ngoh GA, Bachschmid MM, et al. Mitofusins are required for angiogenic function and modulate different signaling pathways in cultured endothelial cells[J]. J Mol Cell Cardiol, 2011, 51(6): 885–893. doi: 10.1016/j.yjmcc.2011.07.023
    [103]
    Schuler MH, Hughes AL. OPA1 and angiogenesis: beyond the fusion function[J]. Cell Metab, 2020, 31(5): 886–887. doi: 10.1016/j.cmet.2020.04.014
    [104]
    Zorzano A, Liesa M, Palacin M. Mitochondrial dynamics as a bridge between mitochondrial dysfunction and insulin resistance[J]. Arch Physiol Biochem, 2009, 115(1): 1–12. doi: 10.1080/13813450802676335
    [105]
    Ong SB, Kalkhoran SB, Cabrera-Fuentes HA, et al. Mitochondrial fusion and fission proteins as novel therapeutic targets for treating cardiovascular disease[J]. Eur J Pharmacol, 2015, 763(Pt A): 104–114. doi: 10.1016/j.ejphar.2015.04.056
    [106]
    Zhang J, Liu W, Liu J, et al. G-protein β2 subunit interacts with mitofusin 1 to regulate mitochondrial fusion[J]. Nat Commun, 2010, 1: 101. doi: 10.1038/ncomms1099
    [107]
    Kitada M, Ogura Y, Monno I, et al. Sirtuins and type 2 diabetes: role in inflammation, oxidative stress, and mitochondrial function[J]. Front Endocrinol (Lausanne), 2019, 10: 187. doi: 10.3389/fendo.2019.00187
    [108]
    Kendrick AA, Choudhury M, Rahman SM, et al. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation[J]. Biochem J, 2011, 433(3): 505–514. doi: 10.1042/BJ20100791
    [109]
    Yang L, Zhang J, Xing W, et al. SIRT3 deficiency induces endothelial insulin resistance and blunts endothelial-dependent vasorelaxation in mice and human with obesity[J]. Sci Rep, 2016, 6: 23366. doi: 10.1038/srep23366
    [110]
    Kim M, Lee JS, Oh JE, et al. SIRT3 overexpression attenuates palmitate-induced pancreatic β-cell dysfunction[J]. PLoS One, 2015, 10(4): e0124744. doi: 10.1371/journal.pone.0124744
    [111]
    Elizabeth MPM, Alarcon-Aguilar FJ, Clara OC, et al. Pancreatic β-cells and type 2 diabetes development[J]. Curr Diabetes Rev, 2017, 13(2): 108–121. doi: 10.2174/1573399812666151020101222
    [112]
    Eizirik DL, Pasquali L, Cnop M. Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure[J]. Nat Rev Endocrinol, 2020, 16(7): 349–362. doi: 10.1038/s41574-020-0355-7
    [113]
    Wang W, Wang Y, Long J, et al. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells[J]. Cell Metab, 2012, 15(2): 186–200. doi: 10.1016/j.cmet.2012.01.009
    [114]
    Rato L, Duarte AI, Tomás GD, et al. Pre-diabetes alters testicular PGC1-α/SIRT3 axis modulating mitochondrial bioenergetics and oxidative stress[J]. Biochim Biophys Acta, 2014, 1837(3): 335–344. doi: 10.1016/j.bbabio.2013.12.008
    [115]
    Sebastián D, Hernández-Alvarez MI, Segalés J, et al. Mitofusin 2 (Mfn2) links mitochondrial and endoplasmic reticulum function with insulin signaling and is essential for normal glucose homeostasis[J]. Proc Natl Acad Sci U S A, 2012, 109(14): 5523–5528. doi: 10.1073/pnas.1108220109
    [116]
    Sebastián D, Sorianello E, Segalés J, et al. Mfn2 deficiency links age-related sarcopenia and impaired autophagy to activation of an adaptive mitophagy pathway[J]. EMBO J, 2016, 35(15): 1677–1693. doi: 10.15252/embj.201593084
    [117]
    Jheng HF, Tsai PJ, Guo SM, et al. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle[J]. Mol Cell Biol, 2012, 32(2): 309–319. doi: 10.1128/MCB.05603-11
    [118]
    Lin HY, Weng S, Chang YH, et al. The causal role of mitochondrial dynamics in regulating insulin resistance in diabetes: link through mitochondrial reactive oxygen species[J]. Oxid Med Cell Longev, 2018, 2018: 7514383. doi: 10.1155/2018/7514383
    • Related Articles

  • Related Articles

    [1]Miao Xu, Yan Gao, Wenjie Yin, Qinghuai Liu, Songtao Yuan. RNA-sequencing expression profile and functional analysis of retinal pigment epithelium in atrophic age-related macular degeneration[J]. The Journal of Biomedical Research, 2024, 38(5): 500-511. DOI: 10.7555/JBR.37.20230320
    [2]Yan Chen, Xiaoxin He, Jiachen Cai, Qian Li. Functional aspects of the brain lymphatic drainage system in aging and neurodegenerative diseases[J]. The Journal of Biomedical Research, 2024, 38(3): 206-221. DOI: 10.7555/JBR.37.20230264
    [3]Wen Zhang, Jiahui Wang, Luyao Yang, Yuyun Shao, Hongjun Peng, Longfeng Jiang, Liang Sheng. Hepatic SIRT6 protects against cholestatic liver disease primarily via inhibiting bile acid synthesis[J]. The Journal of Biomedical Research. DOI: 10.7555/JBR.38.20240172
    [4]Ruxu Sun, Hongjing Zhu, Ying Wang, Jianan Wang, Chao Jiang, Qiuchen Cao, Yeran Zhang, Yichen Zhang, Songtao Yuan, Qinghuai Liu. Circular RNA expression and the competitive endogenous RNA network in pathological, age-related macular degeneration events: A cross-platform normalization study[J]. The Journal of Biomedical Research, 2023, 37(5): 367-381. DOI: 10.7555/JBR.37.20230010
    [5]Jie Wen, Tingyu Pan, Hongyan Li, Haixia Fan, Jinhua Liu, Zhiyou Cai, Bin Zhao. Role of mitophagy in the hallmarks of aging[J]. The Journal of Biomedical Research, 2023, 37(1): 1-14. DOI: 10.7555/JBR.36.20220045
    [6]Haoran Jia, Tianwu Xie. Tracers progress for positron emission tomography imaging of glial-related disease[J]. The Journal of Biomedical Research, 2022, 36(5): 321-335. DOI: 10.7555/JBR.36.20220017
    [7]Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
    [8]Xunxian Liu, Zemin Yao. Insensitivity of PI3K/Akt/GSK3 signaling in peripheral blood mononuclear cells of age-related macular degeneration patients[J]. The Journal of Biomedical Research, 2017, 31(3): 248-255. DOI: 10.7555/JBR.31.20160096
    [9]Sang-Yong Eom, Dong-Hyuk Yim, Jung-Hyun Kim, Joo-Byung Chae, Yong-Dae Kim, Heon Kim. A pilot exome-wide association study of age-related cataract in Koreans[J]. The Journal of Biomedical Research, 2016, 30(3): 186-190. DOI: 10.7555/JBR.30.2016K0002
    [10]Yuguang Shi. Emerging roles of cardiolipin remodeling in mitochondrial dysfunction associated with diabetes, obesity, and cardiovascular diseases[J]. The Journal of Biomedical Research, 2010, 24(1): 6-15.

Catalog

    Figures(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article has an altmetric score of 2
    Article has an altmetric score of 2
    Article views (3246) PDF downloads (296) Cited by()
    Related

    ©2023 by the Editorial Department of the Journals of Nanjing Medical University. All rights reserved.   苏ICP备05071376号-5

    Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail: info@rhhz.net  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return